These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 19513561)

  • 1. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
    Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
    Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
    Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
    J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
    Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
    Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2021 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
    Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
    Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
    Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
    Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.